PATENT CLAIM ANALYSIS

Application Number: 15781742
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "019400"]

Abstract:
The present invention relates to series of compounds as an inhibitor targeting Proliferating Cell Nuclear Antigen (PCNA). Pharmaceutical compositions of those compounds and methods of using them in the treatment of cancer are within the scope of this disclosure.

Claim (Index 2):
The compound of  claim 1 , wherein A is:\n hydrogen, or \u2014(CH)R 1 R 2 , wherein R 1  is hydrogen and R 2  is hydrogen, amino, guanidino, a C 1 -C 6  alkylamino, a C 1 -C 6  alkylguanidino, aminosulfone, a C 1 -C 6  N-alkyl aminosulfone, a C 1 -C 12  alkyl, a C 1 -C 12  cycloalkyl, a C 1 -C 12  heterocyclyl, a C 1 -C 12  aryl, a C 1 -C 12  substituted aryl, a C 1 -C 12  heteroaryl, a C 1 -C 12  substituted heteroaryl, a C 1 -C 12  aralkyl, a C 1 -C 12  substituted aralkyl, a C 1 -C 12  heteroaralkyl, or a C 1 -C 12  substituted heteroaralkyl.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 94.0
- Lexical Diversity: 1.19444
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13991321', '14901314', '15099837', '15948122', '10327813']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8080244880574499
- 35 USC 102 Novelty (BERT): 0.5036857296208223
- Combined Prediction Score: 0.7775906122137871
- Mean Citation Score: 278.127598
- Max Citation Score: 282.24213
- Similarity Product: 223.79692509879288

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test